This fall marks the first time that vaccines will be available to fight the triple threat of Covid-19, flu and respiratory syncytial virus, or RSV, which pose an increased risk to young children, elderly adults and immunocompromised people.

Michael Greenberg, medical head of vaccines in North America at Sanofi ADR (Nasdaq: SNY), says last fall’s “tripledemic” — when kids with RSV filled pediatric hospital units as the flu and coronavirus circulated in lockstep — is still fresh on people’s minds.

“What…

[wpcode id="4722"]

[zmauto id = 1]